Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 2, 2007, Pages 97-104

  Kovarik, John M ^a,b   Hartmann, Stefan ^a,b   Bartlett, Michael ^a,b   Riviere, Gilles Jacques ^a,b   Neddermann, Daniel ^a,b   Wang, Yibin ^a,b   Port, Andreas ^a   Schmouder, Robert L ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b FOCUS Clinical Drug Development GmbH   (Germany)

Author keywords

Absolute bioavailability; Fingolimod; Immunosuppressants; Reversible metabolism

Indexed keywords

DRUG METABOLITE; FINGOLIMOD; FINGOLIMOD PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE COUNT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS NODE DISEASE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HEART; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 33947376484     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.535     Document Type: Article

References (11)

1. Brinkmann V, Lynch KR. FTY720: targeting C-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569-575.
2. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004; 26: 585-587.
3. Tedesco-Silva H, Mourad C, Kahan BJ, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79: 1553-1560.
4. Kovarik JM, Schmouder RL, Barilla D, et al. Multiple-dose FTY720: tolerability pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004; 44: 532-537.
5. Schmouder RL, Barilla D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006; 46: 895-904.
6. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism. Drug Metab Rev 2002; 34: 83-448.
7. European Medicines Evaluation Agency. Note For Guidance on The Investigation of Bioavailability and Bioequivalence. 1991.
8. Consensus Workshop: is there a need for more precise definitions of bioavailability? Eur J Clin Pharmacol 1991; 40: 123-126.
9. Ferry JJ, Horvath AM, Bekersky I, et al. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 1988; 28: 81-87.
10. Kovarik JM, Schmouder RL, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004; 57: 586-591.
11. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 2001; 40: 4893-4903.